Tracy George, MD, is a professor at the University of Utah and vice chair of clinical affairs at the University of New Mexico.

Bezuclastinib Exhibits Superior Disease Biomarker Reduction in NonAdvSM, With Tracy George, MD

A primary analysis of the phase 3 SUMMIT trial has shown that patients with 

non-advanced systemic mastocytosis (NonAdvSM)

 who received treatment with bezuclastinib exhibited improvements in symptom burden and biomarkers of disease compared to placebo.

67th American Society of Hematology (ASH) Annual Meeting and Exposition

 by Tracy George, MD, professor at the University of Utah and vice chair of clinical affairs at the University of New Mexico, these data support the use of bezuclastinib to reduce NonAdvSM disease burden, thereby taking advantage of its possibly disease-modifying impact.

“This is really exciting work, because not only do patients with non-advanced systemic mastocytosis respond clinically to bezuclastinib, but we are actually seeing disease modification in the bone marrow,” George told 

 in an exclusive interview. “Bone marrow mast cells are removed from the bone marrow, change their shape to become normal, and they normalize their immunophenotype. And so, you go from bone marrows which are hypercellular with dense mast cell aggregates to bone marrows which are normally cellular and essentially look normal after treatment with bezuclastinib.”

George’s presentation was based on the registration-directed part 2 of the SUMMIT trial. Investigators included patients with NonAdvSM who had inadequate symptom control despite best supportive care (BSC) mediations. The primary endpoint was 24-week mean change from baseline in Mastocytosis Symptom Severity Daily Diary (MS2D2) total symptom score (TSS), which is a patient-reported outcome measure of symptom severity in NonAdvSM.

A total of 179 patients were included in part 2 of SUMMIT; of these, 119 received bezuclastinib once daily plus BSC, while 60 received placebo plus BSC. The median age was 51 (range, 23-78) years, and mean baseline MS2D2 TSS was 55.6 (standard deviation [SD], 19.8). Additionally, 82% of patients had indolent systemic mastocytosis, 11% had bone marrow mastocytosis, and 7% had smoldering systemic mastocytosis.

At week 24, investigators saw significantly greater symptom improvement among patients treated with bezuclastinib compared to those receiving placebo (least squares mean MS2D2 TSS change: -24.3; 95% CI, -27.6 to -21.1 vs. -15.4; 95% CI, -19.6 to -11.2; 

 = .0001). A ≥50% reduction was also achieved in serum tryptase in 87.4% of bezuclastinib-treated patients versus 0% on placebo (

Investigators also saw more patients receiving bezuclastinib achieved ≥50% reductions in KIT D816V variant allele frequency, serum tryptase, bone marrow MCs (

 = .01), and ≥30% reduction in MS2D2 TSS (

Additionally, most treatment-emergent adverse events were low grade and reversible. The most common in any treatment group were hair color changes (69.5% in bezuclastinib vs 5% in placebo), altered taste (23.7% vs 0%), nausea (22% vs 13.3%), increased ALT/AST (22% vs 6.6%), headache (17.8% vs 11.7%), alopecia (11.9% vs 3.3%), and increased ALP (10.2% vs 3.3%).

Ultimately, George and colleagues determined that bezuclastinib exhibited statistically and clinically significant improvements in both symptom burden and disease biomarkers compared to placebo in patients with NonAdvSM.

“What’s exciting is that these are the results from this pivotal SUMMIT trial, which was treating patients with non-advanced systemic mastocytosis,” George said. “What I’m really looking forward to is our results from the APEX trial, which is treating patients with advanced systemic mastocytosis with bezuclastinib. I expect it’s going to be exciting; I’m hoping to see similar results from that trial.”

Editor's Note: George reports disclosures with Incyte, Celgene/BMS, Beckman Coulter, Cogent Biosciences, and Blueprint Medicines.

George T, Boggs N, Patel J, et al. The effect of bezuclastinib on the pathobiology of mastocytosis: Changes in BM mast cells, tryptase, and KIT p.D816V variant allele frequency from the pivotal SUMMIT trial. Abstract presented at the 67th American Society of Hematology Annual Meeting. Orlando, FL. December 6-9, 2025.

Rein L, Boggs N, Bose P, et al. Efficacy and safety results from the primary analysis of the Pivotal Summit Trial: Bezuclastinib in adults with non-advanced systemic mastocytosis. Blood. 2025;146(Supplement 1):80-80. 

Videos

George highlights bezuclastinib’s effect on bone marrow systemic mastocytosis, emphasizing the drug’s potential in reducing symptom burden.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hematology

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

There is a potential causal link between 

 and depression, according to new findings, highlighting the value of mental health screening among patients with the skin disease.

Such findings on the association between mental health and psoriasis resulted from a recently published analysis by investigators such as Xixing Ma, MD, from the Second Hospital of Hebei Medical University (HBMU). In this analysis, Ma and coauthors pointed to prior speculation suggesting inflammation may function as a pathophysiological association between psoriasis and depression.

Most current studies on the topic, however, were described as observational research-based. They also highlighted such studies’ limited sample sizes and consequent susceptibility to potential confounding variables or reverse causality.

“Our study represents the first comprehensive investigation using MR methodology to establish the causal relationship between PSO and depression, addressing a critical gap in the current literature and potentially informing more targeted therapeutic strategies,” Ma and colleagues wrote.

 “Therefore, our study aims to explore the causal relationship between PSO and depression using a two-sample MR approach.”

The investigative team set out to evaluate psoriasis's potential causal connection with depression, applying a 2-sample Mendelian randomization (MR) framework to explore the subject. Their study was conducted in accordance with the 3 fundamental MR assumptions, the first of which being the instrumental genetic variants must show a significant link with the exposure (psoriasis). Additionally, Ma et al noted they must be independent of confounding variables that could affect both exposure and outcome, and they must influence the mental health outcome exclusively via exposure rather than through alternative biological pathways, thereby avoiding horizontal pleiotropy.

To assess the genetic correlation between psoriasis and depression, Ma and coauthors analyzed Z-score–based summary statistics from several genome-wide association studies (GWAS). These studies were done in European cohorts. Only GWAS datasets that met the investigative team's predefined criteria were highlighted, including consistent ancestral backgrounds, larger sample numbers, and a lack of overlap between the psoriasis and depression samples. These datasets were included to minimize bias and strengthen any causal inference.

Ma and colleagues utilized genetic variants as instrumental variables within their MR design, with the inverse variance weighted (IVW) method functioning as the principal analytical approach. Additionally, the investigative team supplemented this with MR Steiger testing for the purposes of confirming causality's direction. It was also supplemented with colocalization analyses as the team sought to explore whether both traits share any underlying causal variants.

These data demonstrated a link between genetic liability to psoriasis and an elevated depression risk (OR 1.35, 95% CI 1.14–1.59, 

 = .004). This association identified by Ma et al was shown to have been consistent across several complementary MR approaches. These approaches included MR-Egger and MR-PRESSO. In findings resultinf from directionality testing via MR Steiger, a causal influence of psoriasis on depression was identified. Additionally, the investigators' colocalization analysis pointed to rs12189871 as a shared causal locus implicated in both of the phenotypes.

Growing interest in any links between psoriasis and mental health outcomes like depression has prompted a variety of previous investigations, and Ma and colleagues' findings contribute additional evidence supporting a causal relationship between the inflammatory skin disease and depression. While the underlying biological mechanisms were still described by the investigators as not yet elucidated, previous data has indicated that genetic variation involving the HLA-C region may heighten a patient's susceptibility to depressive symptoms.

“Future research should focus on elucidating the underlying biological mechanisms, particularly the role of shared inflammatory pathways and specific genetic loci such as those within the HLA region identified in our study,” they concluded.

Guo Bingshen, Bai Yanzhi, Ma Xixing, et al. Genetic Susceptibility to Psoriasis Increases Risk of Depression: Evidence From a Mendelian Randomization Study, International Journal of Clinical Practice, 2025, 9238266, 8 pages, 2025. 

Bell KA, Balogh EA, Feldman SR. An update on the impact of depression on the treatment of psoriasis. Expert Opin Pharmacother. 2021 Apr;22(6):695-703. 

Articles

Recent findings suggest a potential causal link between psoriasis and depression, emphasizing the importance of mental health screening in psoriasis patients. A study led by Xixing Ma utilized a two-sample Mendelian randomization (MR) approach to explore this relationship, addressing limitations of previous observational studies. The research identified a genetic correlation between psoriasis and increased depression risk, with rs12189871 as a shared causal locus. While the biological mechanisms remain unclear, the study highlights the need for further research into shared inflammatory pathways and genetic loci, particularly within the HLA region.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Potential Causal Relationship Identified Between Depression, Psoriasis

VAYHIT3: Ianalumab Reduces Bleeding, Depletes B Cells in Immune Thrombocytopenia, With Philip Choi, MBBS, PhD

Secondary analyses of the phase 2 VAYHIT3 trial support the efficacy profile of ianalumab, including rapid and profound B-cell depletion and reductions in bleeding events in heavily pretreated adults with 

 by Philip Choi, MBBS, PhD, an associate professor at the Australian National University College of Science and Medicine.

“VEHIT-3 is very much a proof-of-mechanism study. It wasn’t designed or powered to show superiority over other therapies. It was conducted in patients with severe, refractory ITP. These were predominantly older patients compared with typical first- or second-line ITP studies,” Choi said in an interview with 

. “Despite that, and despite heavy prior immunosuppression, a meaningful proportion of patients derived significant benefit with very little toxicity. That’s the key message: BAFF receptor inhibitors may have an important role even for patients with very severe refractory ITP.”

Ianalumab, a fully human IgG1 monoclonal antibody, is being investigated for its potential to treat various B cell-driven autoimmune diseases. The drug binds the BAFF receptor and depletes B cells through antibody-dependent cellular cytotoxicity while concurrently blocking BAFF.

Primary analysis from VAYHIT3, a phase 2 open-label, single-arm study, was released earlier this year with a primary endpoint, confirmed platelet response (ConfR). The current analysis focuses on secondary outcomes, including the depth and duration of B-cell depletion, immunoglobulin trends, bleeding events, and safety. Responses assessed in the study included stable response (SR) and complete response (CR).

The study enrolled adults with primary ITP and a platelet count <30 G/L, previously treated with at least a corticosteroid (CS) and a thrombopoietin receptor agonist.

Upon analysis, Choi and colleagues observed rapid and potent B-cell depletion, with a median percent change from baseline of –97.6% before the 2nd infusion at week 5 and –99.9% before the 4th infusion at week 13. By the data cutoff, the median time to B-cell recovery was not estimable for investigators.

Subgroup analysis of ConfR rates at week 25 suggested benefit across all subgroups, including 40% for patients with 2 to 3 prior treatments, 67% for 4 to 5, and 33% for ≥6 prior therapies; 42% for patients aged 18 to <65 years and 50% for those ≥65; and 48% of female patients versus 40% of male patients. The proportion of patients achieving CR increased from 10% at Week 9 to 22% at week 25.

Investigators reported substantial reductions in both the number and severity of bleeding events. Post-baseline, all but 1 patient maintained IgG values ≥5 g/L. At study entry, 59% of patients reported bleeding events, with 44% grade 1. After the second infusion, bleeding events decreased substantially, and by week 25, 22% of evaluable patients reported any-grade bleeding, with 16% grade 1. No new safety signals emerged during longer follow-up.

“We look forward to biomarker analyses over the next 12–18 months to help identify which patients are most likely to benefit from BAFF receptor inhibition,” Choi said. “Another open question is whether B-cell reconstitution will eventually lead to loss of response in some patients. Long-term data are still needed.”

Editor’s Note: Choi reports relevant disclosures with Janssen Cilag, SOBI, Novartis, Amgen, and Sanofi.

Choi P, Bradbury C, Gonzalez-Lopez T, et al. Secondary analysis results from VAYHIT3, a phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy. Abstract presented at the 67th American Society of Hematology Annual Meeting. Orlando, FL. December 6-9, 2025.

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses. Novartis. Published 2025. Accessed December 9, 2025. 

https://www.novartis.com/news/media-releases/novartis-ianalumab-significantly-extends-disease-control-patients-immune-thrombocytopenia-only-four-once-monthly-doses

Data from VAYHIT3 presented at ASH 2025 suggest efficacy and safety of ianalumab in patients with primary immune thrombocytopenia. 


Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Credit: University Hospital Southhampton 

A phase 3 study showed that the standard quality (SQ) house dust mite sublingual immunotherapy (SLIT) tablet was well tolerated in children aged 5 – 7 years with house dust mite

In children, house dust mite sensitization increases the risk of developing allergic asthma. Allergen immunotherapy for house dust mite allergic asthma has shown promise in adults, but there is a lack of evidence for this treatment in children.

Graham Roberts, from the David Hide Asthma and Allergy Centre, St Mary's Hospital, and colleagues conducted MT-11, a phase 3, randomized, double-blind, placebo-controlled trial, to assess the efficacy and safety of the SQ house dust mite SLIT tablet in children aged 5 – 17 years with house dust mite allergic asthma. The primary endpoint was the yearly rate of clinically relevant asthma exacerbations.

The study included 533 children with a recent history of asthma exacerbations despite receiving inhaled corticosteroids or long-acting beta-agonists. Children were randomized to receive daily SQ house dust mite SLIT-tablet or placebo for 24 – 30 months.

As a result of the COVID-19 pandemic, asthma exacerbations occurred far less frequently than anticipated, which contributed to the study not meeting its primary endpoint. The annual rate ratio for clinically relevant asthma exacerbations was 0.89 (95% CI, 0.60–1.30), suggesting a benefit with the house dust mite SLIT tablet but not a clear advantage over placebo. The study observed changes in the house dust mite-specific IgE, IgG4, and IgE-BF in the SLIT arm but not the placebo arm.

“The overall annualized rate of asthma exacerbations was low in both groups (0.21 with the SQ HDM SLIT-tablet and 0.18 with placebo), which could largely be attributed to the approximately 67% decrease in asthma exacerbation rate during the COVID-19 pandemic compared to the pre-pandemic rate,” the team wrote.

Before the pandemic, the placebo group in MT-11 experienced an exacerbation rate of 0.39, much lower than the 1.4 rate the study had expected. This expectation was based on an earlier study by Lanier and colleagues, which enrolled children with inadequately controlled asthma despite medium- or high-dose inhaled corticosteroids, with or without other controller therapy.

 However, the rate actually observed in the MT-11 trial is closer to what later pediatric trials reported, where placebo groups had yearly exacerbation rates between 0.43 and 0.87.

“This observation indicates that management of asthma symptoms in children has generally improved since the completion of the Lanier et al. trial, potentially due to reduced outdoor pollution, changes in healthcare utilization, and improved asthma self-management,” investigators added.

 “There were considerably lower levels of respiratory tract infections during the COVID-19 pandemic, due to imposed social distancing measures and restricted social interaction.”

Like dust mites, viral respiratory infections are another trigger for asthma exacerbations in children. Other explanations that may explain why asthma exacerbations went down during the pandemic include children being more likely to go to the hospital for asthma or wheezing and being more likely to adhere to asthma controller medication due to increased awareness of health risks associated with asthma and COVID-19.

Despite these findings, the trial showed the house dust mite SLIT tablet was well tolerated over the 2 years, with most treatment-related adverse events mild or moderate in severity. Under 2% of participants discontinued due to treatment-related adverse events. The most common treatment-related adverse events were local application site reactions, including oral pruritus, throat irritation, ear pruritus, and upper abdominal pain. Investigators observed no increased incidence of asthma-related events, no anaphylaxis, and no adrenaline use in the house dust mite SLIT-tablet arm.

“The findings from the MT-11 and MT-12 trials provide important safety data to support decision-making for [house dust mite allergen immunotherapy] use in a pediatric population with [house dust mite] respiratory allergy,” investigators wrote.

Roberts G, Just J, Nolte H, Hels OH, Emeryk A, Vidal C. SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial. 

. 2025;80(12):3401-3411. doi:10.1111/all.70073

Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. 

. 2009;124(6):1210-1216. doi:10.1016/j.jaci.2009.09.021

A phase 3 trial evaluated the efficacy and safety of the SQ house dust mite SLIT tablet in children with allergic asthma. Despite the COVID-19 pandemic affecting asthma exacerbation rates, the study suggested potential benefits of the SLIT tablet, although it did not meet its primary endpoint. The trial demonstrated that the SLIT tablet was well tolerated, with most adverse events being mild or moderate. The findings provide valuable safety data for using house dust mite allergen immunotherapy in pediatric populations with respiratory allergies.

Study shows house dust mite SLIT therapy is safe in children with allergic asthma, though COVID-19–related drops in exacerbations impacted the primary endpoint.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

House Dust Mite SLIT Tablet Well Tolerated in Children With Allergic Asthma

Claudia Morris, MD, is a professor of pediatrics and emergency medicine at Emory University and a pediatric emergency medicine physician at Children's Health Care of Atlanta.

PECARN STArT Fails to Improve Time-to-Crisis Resolution in SCD Pain, With Claudia Morris, MD

The PECARN STArT trial has failed to meet its primary outcome of time-to-crisis resolution (TCR) in patients with 

 who have developed vaso-occlusive pain episodes (VOE).

 in Orlando, Florida, by Claudia Morris, MD, professor of pediatrics and emergency medicine at Emory University School of Medicine, these results have consigned PECARN STArT to a long list of prior phase 3 randomized clinical trials which failed to meet their primary outcomes. These trials face significant challenges due to shorter hospital stays and interpatient variability in TCR.

“Unfortunately, the study was closed early by the Data Safety Monitoring Board. Not for any safety reasons, but for failure to meet time-to-crisis resolution,” Morris told 

 in an exclusive interview. “And we joined every other phase 3 trial in acute pain for not meeting this outcome measure.”

VOEs are the leading cause of emergency department (ED) visits and hospitalizations for patients with SCD. During SCD-VOEs, patients develop an acute arginine (Arg) deficiency, which is associated with adverse clinical outcomes such as longer TCR and greater total parental opioid use (TPO) during hospitalization.

PECARN STArT was a multicenter, double-blind, phase 3 trial of intravenous Arg therapy. Patients aged 3-21 years with SCD-VOE who were actively receiving intravenous opioids utilizing the Pediatric Emergency Care Applied Research Network (PECARN) were included in the study. The primary outcome of TCR was defined as the time from study drug delivery to the last dose of intravenous opioid delivery. Secondary outcomes included TPO, defined as total intravenous morphine equivalents in mg/kg from study drug delivery to last parental opioid, and patient-reported outcomes at admission, discharge, and 7-12 days post-discharge.

Within 12 hours of receiving their first opioid dose, patients were randomly assigned in a 1:1 ratio to either a 1-time leading dose of intravenous Arg (200 mg/kg with a maximum of 20g) followed by a standard dose of 100 mg/kg (maximum 10g 3 times per day) or a normal saline placebo at equivalent volumes and duration as the study drug.

A total of 2629 patients were screened, of whom 1034 were eligible. Ultimately, 271 were randomized, with 129 receiving Arg and 142 receiving placebo. Mean age was 14 years (standard deviation [SD] +/-4), 51% of patients were male, 71% had Hb-SS, 76% were on hydroxyurea, and 41% had chronic pain defined as SCD-pain ≥15 days per month for the last 6 months.

TCR was similar in the Arg arm versus placebo (82 +/- 80 vs 89 +/- 152 hours; 

 = .98). TPO was also similar across both arms (2.6 +/- 4.5 vs 1.9 +/- 2.8 mg/kg; 

 = .33). There were no differences in safety outcomes, adverse events, pain scores, or patient-reported pain interference. A total of 54 participants developed acute chest syndrome.

Ultimately, the trial was halted early for futility to achieve the primary outcome of TCR. Morris and colleagues attribute this decision to larger than expected site variation, outliers, and SD. Sample size recalculation based on STArT data would require randomization of >900 subjects.

“I think the silver lining is identifying a subgroup of patients who may truly benefit from arginine therapy,” Morris said. “It’s hard to know if their biochemistry is different from patients who come in with chest pain and no acute chest syndrome or if it’s just the fact that patients with acute chest syndrome are in the hospital for over 7 days. But it raises additional questions that we need to answer, and I think that the jury is still out for treatment with arginine therapy.”

Editor’s Note: Morris reports disclosures with CSL Behring, Roche, and Trility.

Morris C, Ahmad F, Airewele G, et al. Sickle Cell Disease Treatment With Arginine Therapy (STArT) – Results of a Phase-3 Randomized Controlled Trial. Abstract presented at the 67

 American Society of Hematology Annual Meeting. Orlando, FL. December 6-9, 2025.

Novelli EM, Gladwin MT. Crises in Sickle Cell Disease. Chest. 2016;149(4):1082-1093. 

Morris discusses this latest trial in a long list of phase 3 studies which failed to evaluate arginine therapy’s value in vaso-occlusive pain episodes in SCD.

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Natalia Nedelkopoulou, MD, is a consultant pediatric gastroenterologist at Sheffield Children's Hospital.

Nedelkopoulou emphasizes the importance of structured and multidisciplinary transition programs for young patients with IBD and HPB disease.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Unraveling the Complexities of Concomitant IBD and Hepatobiliary Disease, With Natalia Nedelkopoulou, MD

Hanny Al-Samkari, MD, is the Peggy S. Blitz Endowed Chair in hematology and oncology at the Massachusetts General Hospital and an associate professor of medicine at Harvard Medical School.

Al-Samkari discusses the positive results from the VAYHIT2 trial, which investigated ianalumab in combination with eltrombopag in adults with ITP.

Ianalumab Improves Stable Response, Reduces Fatigue in ITP, With Hanny Al-Samkari, MD

Teva submitted an NDA on olanzapine extended-release injectable suspension (TEV-‘749) for adult schizophrenia to the FDA.

FDA News

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

VTL-308 post-hoc analysis shows corticosteroids may decrease AKI risk in severe alcohol-associated hepatitis, but don’t affect recovery. 


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Steroids Linked to Reduced Risk of Acute Kidney Injury in Severe Alcohol-Associated Hepatitis

This study aimed to compare the efficacy and safety of monoclonal antibodies (mAb) for moderate-to-severe atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dupilumab Superior in Analysis of Monoclonal Antibodies for Atopic Dermatitis

Sayna Norouzi, MD, is an assistant professor of medicine, clinical nephrologist, and founder and director of the glomerular disease and polycystic kidney disease clinics at Loma Linda University Medical Center.

In this segment, the panel discusses how the treatment landscape for IgA nephropathy is evolving with the introduction of disease-targeted therapies.

Video Series

Current Disease-Modifying Treatment Options in IgAN

Healthcare professionals discuss strategies for effectively lowering LDL cholesterol in patients post-cardiac events, emphasizing early intervention and tailored therapies.

Optimizing the Timing of PCSK9 Therapy After an ASCVD Event

The panel examines drug classes targeting the BAFF and APRIL pathways, which play key roles in the production and regulation of IgA-secreting plasma cells.

Exploring the Therapeutic Potential of B-Cell Modulation in IgAN

Princess Ogbogu, MD, from the University of Hospitals Rainbow Babies & Children’s Hospital

This HCPLive Five features advancements in asthma, immunology, and allergy that were presented at the ACAAI 2025 meeting in Orlando.

HCPLive Five at ACAAI 2025

Healthcare professionals explore effective strategies for LDL cholesterol management, emphasizing patient involvement and innovative therapies for optimal outcomes.

Latest News

Bezuclastinib Exhibits Superior Disease Biomarker Reduction in NonAdvSM, With Tracy George, MD

Potential Causal Relationship Identified Between Depression, Psoriasis

VAYHIT3: Ianalumab Reduces Bleeding, Depletes B Cells in Immune Thrombocytopenia, With Philip Choi, MBBS, PhD

House Dust Mite SLIT Tablet Well Tolerated in Children With Allergic Asthma

PECARN STArT Fails to Improve Time-to-Crisis Resolution in SCD Pain, With Claudia Morris, MD